Table 1.
Baseline Clinical Characteristics Between the MACE and Non-MACE Groups.
| Variable | MACE (n = 63) |
Non-MACE (n = 1495) |
χ2/Z | P-value |
|---|---|---|---|---|
| Demographic and clinical data, n (%) | ||||
| Male | 46 (73.0) | 1120 (74.9) | 0.116 | .733 |
| Age ≥65 years | 32 (50.8) | 340 (22.7) | 26.171 | <.001 |
| BMI | 24.22 (22.67, 27.34) | 25.16 (23.05, 27.55) | −1.119 | .263 |
| Smoking | 29 (46.0) | 780 (52.2) | 0.914 | .339 |
| Dyslipidemia | 36 (57.1) | 846 (56.6) | 0.008 | .931 |
| Hypertension | 35 (55.6) | 880 (58.9) | 0.273 | .601 |
| Diabetes mellitus | 14 (22.2) | 380 (25.4) | 0.327 | .568 |
| History of stroke | 16 (25.4) | 206 (13.8) | 6.678 | .010 |
| History of TIA | 0 (0.0) | 5 (0.3) | 0.211 | .646 |
| HF | 20 (31.7) | 138 (9.2) | 33.629 | <.001 |
| CGS | 8 (12.7) | 17 (1.1) | 51.178 | <.001 |
| Family history of CAD | 5 (7.9) | 214 (14.3) | 2.036 | .154 |
| UA | 15 (23.8) | 601 (40.2) | 6.794 | .009 |
| STEMI | 34 (54.0) | 660 (44.1) | 2.360 | .124 |
| NSTEMI | 14 (22.2) | 234 (15.7) | 1.950 | .163 |
| Laboratory data, M(Q1, Q3) | ||||
| WBC count (109/L) | 8.95 (7.39, 11.35) | 8.00 (6.41, 10.49) | −1.707 | .088 |
| Platelet count (109/L) | 213.00 (176.00, 245.00) | 215.00 (179.50, 252.00) | −0.744 | .457 |
| Neutrophil count (109/L) | 6.82 (4.86, 9.22) | 5.47 (3.97, 8.29) | −2.522 | .012 |
| Lymphocyte count (109/L) | 1.29 (0.87, 1.72) | 1.67 (1.22, 2.29) | −3.464 | <.001 |
| Monocyte count (109/L) | 0.47 (0.34, 0.57) | 0.43 (0.32, 0.58) | −0.796 | .426 |
| AISI≥293.46 | 43 (70.5) | 711 (47.6) | 12.306 | <.001 |
| SIRI≥2.45 | 30 (49.2) | 393 (26.3) | 15.486 | <.001 |
| NLRP≥0.018 | 38 (62.3) | 619 (41.5) | 10.365 | <.001 |
| SII ≥628.60 | 46 (75.4) | 758 (50.7) | 14.288 | <.001 |
| dNLR ≥2.30 | 46 (75.4) | 735 (49.2) | 16.108 | <.001 |
| NLR ≥2.67 | 50 (82.0) | 860 (57.6) | 14.379 | <.001 |
| PLR ≥225.49 | 18 (29.5) | 214 (14.3) | 10.645 | <.001 |
| MLR ≥0.33 | 30 (50.0) | 429 (29.3) | 11.703 | <.001 |
| MPV (fL) | 10.40 (9.80, 10.90) | 10.40 (9.80, 11.00) | −0.547 | .585 |
| PDW (%) | 12.20 (11.00, 13.40) | 12.00 (10.90, 13.40) | −0.403 | .687 |
| ALB (g/L) | 39.60 (37.00, 41.40) | 41.39 (38.80, 43.70) | −3.305 | <.001 |
| CK-MB (U/L) | 36.00 (11.00, 123.49) | 16.37 (10.00, 48.00) | −2.702 | .007 |
| Cr (μmol/L) | 76.12 (63.20, 88.70) | 67.00 (58.50, 78.00) | −3.180 | .001 |
| Serum uric acid (μmol/L) | 333.10 (272.80, 391.10) | 327.00 (264.70, 384.45) | −0.669 | .504 |
| Echocardiography, n (%) | ||||
| LA↑ | 26 (45.6) | 431 (32.0) | 4.619 | .032 |
| LVEDD↑ | 18 (29.5) | 337 (22.6) | 1.600 | .206 |
| LVEF <40% | 8 (14.0) | 33 (2.4) | 25.971 | <.001 |
| Coronary angiography, n (%) | ||||
| 1 vessel | 16 (26.23) | 471 (31.57) | 0.776 | .378 |
| 2 vessels | 21 (34.43) | 473 (31.70) | 0.200 | .654 |
| 3 vessels | 24 (39.34) | 548 (36.73) | 0.172 | .678 |
Abbreviations: MACE, major adverse cardiovascular events; BMI, body mass index; TIA, transient ischemic attack; HF, heart failure; CGS, cardiogenic shock; CAD, coronary artery disease; UA, unstable angina; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; WBC, white blood cell; AISI, aggregate index of systemic inflammation (neutrophil*platelet*monocyte-to-lymphocyte ratio); SIRI, systemic inflammation response index (neutrophil*monocyte-to-lymphocyte ratio); NLRP, neutrophil-to-(lymphocyte*platelet) ratio; SII, systemic immune-inflammation index (neutrophil*platelet-to-lymphocyte ratio); dNLR, derived neutrophil-to-lymphocyte ratio (neutrophil/[white blood cell–neutrophil]); NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; MPV, mean platelet volume; PDW, platelet distribution width; ALB, albumin; CK-MB, creatine kinase-MB; Cr, creatinine; LA, left atrium; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction. ↑, above the upper limit of normal values.